{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T02:09:07Z","timestamp":1777860547271,"version":"3.51.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T00:00:00Z","timestamp":1774137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Chongqing Talents Program","award":["cstc2024ycjh-bgzxm0095"],"award-info":[{"award-number":["cstc2024ycjh-bgzxm0095"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"DOI":"10.1186\/s12985-026-03138-w","type":"journal-article","created":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T04:22:43Z","timestamp":1774153363000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dynamic changes in TREX1 and LGALS9 mRNA levels in PBMCs predict HBsAg clearance and treatment responses to Peg-IFN-\u03b1 therapy in HBeAg-negative chronic hepatitis B patients"],"prefix":"10.1186","volume":"23","author":[{"given":"Hao","family":"Pang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinhong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinglin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,22]]},"reference":[{"key":"3138_CR1","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41575-023-00760-9","volume":"20","author":"YC Hsu","year":"2023","unstructured":"Hsu YC, Huang DQ, Nguyen MH. Global burden of hepatitis B virus: current status, missed opportunities and a call for action. Nat Rev Gastroenterol Hepatol. 2023;20:524\u201337.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"3138_CR2","doi-asserted-by":"publisher","first-page":"618","DOI":"10.3390\/v16040618","volume":"16","author":"B Songtanin","year":"2024","unstructured":"Songtanin B, Chaisrimaneepan N, Mend\u00f3za R, Nugent K. Burden, Outcome, and Comorbidities of Extrahepatic Manifestations in Hepatitis B Virus Infections. Viruses. 2024;16(4):618.","journal-title":"Viruses"},{"key":"3138_CR3","unstructured":"Hepatitis B. [https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b]."},{"key":"3138_CR4","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/liv.13246","volume":"37","author":"S Maimone","year":"2017","unstructured":"Maimone S, Caccamo G, Squadrito G, Alibrandi A, Saffioti F, Spinella R, Raffa G, Pollicino T, Raimondo G. A combination of different diagnostic tools allows identification of inactive hepatitis B virus carriers at a single time point evaluation. Liver Int. 2017;37:362\u20138.","journal-title":"Liver Int"},{"key":"3138_CR5","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/hep.28552","volume":"64","author":"J Liu","year":"2016","unstructured":"Liu J, Yang HI, Lee MH, Jen CL, Batrla-Utermann R, Lu SN, Wang LY, You SL, Chen CJ. Serum Levels of Hepatitis B Surface Antigen and DNA Can Predict Inactive Carriers With Low Risk of Disease Progression. Hepatology. 2016;64:381\u20139.","journal-title":"Hepatology"},{"key":"3138_CR6","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr., Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560\u201399.","journal-title":"Hepatology"},{"key":"3138_CR7","doi-asserted-by":"crossref","unstructured":"EASL. 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017, 67:370\u2013398.","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"3138_CR8","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1002\/hep.21612","volume":"45","author":"CM Chu","year":"2007","unstructured":"Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology. 2007;45:1187\u201392.","journal-title":"Hepatology"},{"key":"3138_CR9","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1053\/j.gastro.2010.01.042","volume":"138","author":"JD Chen","year":"2010","unstructured":"Chen JD, Yang HI, Iloeje UH, You SL, Lu SN, Wang LY, Su J, Sun CA, Liaw YF, Chen CJ. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology. 2010;138:1747\u201354.","journal-title":"Gastroenterology"},{"key":"3138_CR10","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.jhep.2012.11.039","volume":"58","author":"S Chevaliez","year":"2013","unstructured":"Chevaliez S, H\u00e9zode C, Bahrami S, Grare M, Pawlotsky JM. Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside\/nucleotide analogue therapy: finite treatment duration unlikely. J Hepatol. 2013;58:676\u201383.","journal-title":"J Hepatol"},{"key":"3138_CR11","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/j.cgh.2021.08.037","volume":"20","author":"YC Hsu","year":"2022","unstructured":"Hsu YC, Wu JL, Tseng CH, Nguyen MH, Lin CW, Hung CL. Severe Acute Exacerbation After Cessation of Nucleos(t)ide Analog for Chronic Hepatitis B: A Real-World Study of Routine Practice. Clin Gastroenterol Hepatol. 2022;20:1413\u2013e14151413.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3138_CR12","first-page":"204993612096502","volume":"7","author":"V Soriano","year":"2020","unstructured":"Soriano V, Barreiro P, Cachay E, Kottilil S, Fernandez-Montero JV, de Mendoza C. Advances in hepatitis B therapeutics. Ther Adv Infect Dis. 2020;7:2049936120965027.","journal-title":"Ther Adv Infect Dis"},{"key":"3138_CR13","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.jhep.2014.05.044","volume":"61","author":"Q Ning","year":"2014","unstructured":"Ning Q, Han M, Sun Y, Jiang J, Tan D, Hou J, Tang H, Sheng J, Zhao M. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial). J Hepatol. 2014;61:777\u201384.","journal-title":"J Hepatol"},{"key":"3138_CR14","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1056\/NEJMoa040431","volume":"351","author":"P Marcellin","year":"2004","unstructured":"Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, Lu ZM, Piratvisuth T, Germanidis G, Yurdaydin C, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004;351:1206\u201317.","journal-title":"N Engl J Med"},{"key":"3138_CR15","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nri2314","volume":"8","author":"AJ Sadler","year":"2008","unstructured":"Sadler AJ, Williams BR. Interferon-inducible antiviral effectors. Nat Rev Immunol. 2008;8:559\u201368.","journal-title":"Nat Rev Immunol"},{"key":"3138_CR16","doi-asserted-by":"publisher","first-page":"15623","DOI":"10.1073\/pnas.95.26.15623","volume":"95","author":"SD Der","year":"1998","unstructured":"Der SD, Zhou A, Williams BR, Silverman RH. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A. 1998;95:15623\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3138_CR17","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.virol.2022.12.014","volume":"579","author":"H Luo","year":"2023","unstructured":"Luo H, Hu X, Li Y, Lei D, Tan G, Zeng Y, Qin B. The antiviral activity of tripartite motif protein 38 in hepatitis B virus replication and gene expression and its association with treatment responses during PEG-IFN-\u03b1 antiviral therapy. Virology. 2023;579:84\u201393.","journal-title":"Virology"},{"key":"3138_CR18","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/cmi.2016.67","volume":"15","author":"G Tan","year":"2018","unstructured":"Tan G, Xiao Q, Song H, Ma F, Xu F, Peng D, Li N, Wang X, Niu J, Gao P, et al. Type I IFN augments IL-27-dependent TRIM25 expression to inhibit HBV replication. Cell Mol Immunol. 2018;15:272\u201381.","journal-title":"Cell Mol Immunol"},{"key":"3138_CR19","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.jhep.2019.12.009","volume":"72","author":"YX Wang","year":"2020","unstructured":"Wang YX, Niklasch M, Liu T, Wang Y, Shi B, Yuan W, Baumert TF, Yuan Z, Tong S, Nassal M, Wen YM. Interferon-inducible MX2 is a host restriction factor of hepatitis B virus replication. J Hepatol. 2020;72:865\u201376.","journal-title":"J Hepatol"},{"key":"3138_CR20","doi-asserted-by":"publisher","first-page":"e0150925","DOI":"10.1128\/jvi.01509-25","volume":"99","author":"X Yu","year":"2025","unstructured":"Yu X, Liu CD, Shen S, Kim ES, Liu Z, Zhang H, Sun N, Liu Y, Martensen PM, Huang Y, Guo H. Interferon alpha-inducible protein 27 (IFI27) inhibits hepatitis B virus (HBV) transcription through downregulating cellular transcription factor C\/EBP\u03b1. J Virol. 2025;99:e0150925.","journal-title":"J Virol"},{"key":"3138_CR21","doi-asserted-by":"publisher","first-page":"6387","DOI":"10.1128\/JVI.00236-10","volume":"84","author":"J Li","year":"2010","unstructured":"Li J, Lin S, Chen Q, Peng L, Zhai J, Liu Y, Yuan Z. Inhibition of hepatitis B virus replication by MyD88 involves accelerated degradation of pregenomic RNA and nuclear retention of pre-S\/S RNAs. J Virol. 2010;84:6387\u201399.","journal-title":"J Virol"},{"key":"3138_CR22","doi-asserted-by":"publisher","first-page":"102894","DOI":"10.1016\/j.dnarep.2020.102894","volume":"94","author":"SR Simpson","year":"2020","unstructured":"Simpson SR, Hemphill WO, Hudson T, Perrino FW. TREX1 - Apex predator of cytosolic DNA metabolism. DNA Repair (Amst). 2020;94:102894.","journal-title":"DNA Repair (Amst)"},{"key":"3138_CR23","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1189\/jlb.2A0713-393RR","volume":"96","author":"J Xu","year":"2014","unstructured":"Xu J, Zoltick PW, Gamero AM, Gallucci S. TLR ligands up-regulate Trex1 expression in murine conventional dendritic cells through type I Interferon and NF-\u03baB-dependent signaling pathways. J Leukoc Biol. 2014;96:93\u2013103.","journal-title":"J Leukoc Biol"},{"key":"3138_CR24","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature09907","volume":"472","author":"JW Schoggins","year":"2011","unstructured":"Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, Rice CM. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature. 2011;472:481\u20135.","journal-title":"Nature"},{"issue":"10","key":"3138_CR25","doi-asserted-by":"publisher","first-page":"BSR20202603","DOI":"10.1042\/BSR20202603","volume":"40","author":"Z Qi","year":"2020","unstructured":"Qi Z, Yan F, Chen D, Xing W, Li Q, Zeng W, Bi B, Xie J. Identification of prognostic biomarkers and correlations with immune infiltrates among cGAS-STING in hepatocellular carcinoma. Biosci Rep. 2020;40(10):BSR20202603.","journal-title":"Biosci Rep"},{"key":"3138_CR26","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1093\/infdis\/jiaf002","volume":"231","author":"R Susp\u00e8ne","year":"2025","unstructured":"Susp\u00e8ne R, Caval V, Khalfi P, Pitr\u00e9 E, Marchio A, Pineau P, Vartanian JP. Cobalt Chloride-Mimicked Hepatocyte Cell Hypoxia Induces TREX1, Leading to Hepatitis B Virus Restriction. J Infect Dis. 2025;231:1559\u201367.","journal-title":"J Infect Dis"},{"key":"3138_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/nrc1527","volume":"5","author":"FT Liu","year":"2005","unstructured":"Liu FT, Rabinovich GA. Galectins as modulators of tumour progression. Nat Rev Cancer. 2005;5:29\u201341.","journal-title":"Nat Rev Cancer"},{"key":"3138_CR28","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nri2536","volume":"9","author":"GA Rabinovich","year":"2009","unstructured":"Rabinovich GA, Toscano MA. Turning \u2018sweet\u2019 on immunity: galectin-glycan interactions in immune tolerance and inflammation. Nat Rev Immunol. 2009;9:338\u201352.","journal-title":"Nat Rev Immunol"},{"key":"3138_CR29","doi-asserted-by":"publisher","first-page":"6078","DOI":"10.1074\/jbc.272.9.6078","volume":"272","author":"J Wada","year":"1997","unstructured":"Wada J, Kanwar YS. Identification and characterization of galectin-9, a novel beta-galactoside-binding mammalian lectin. J Biol Chem. 1997;272:6078\u201386.","journal-title":"J Biol Chem"},{"issue":"Suppl 1","key":"3138_CR30","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1159\/000053623","volume":"122","author":"M Hirashima","year":"2000","unstructured":"Hirashima M. Ecalectin\/galectin-9, a novel eosinophil chemoattractant: its function and production. Int Arch Allergy Immunol. 2000;122(Suppl 1):6\u20139.","journal-title":"Int Arch Allergy Immunol"},{"key":"3138_CR31","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1023\/B:GLYC.0000014090.63206.2f","volume":"19","author":"M Hirashima","year":"2002","unstructured":"Hirashima M, Kashio Y, Nishi N, Yamauchi A, Imaizumi TA, Kageshita T, Saita N, Nakamura T. Galectin-9 in physiological and pathological conditions. Glycoconj J. 2002;19:593\u2013600.","journal-title":"Glycoconj J"},{"key":"3138_CR32","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1080\/15548627.2022.2059747","volume":"18","author":"K Miyakawa","year":"2022","unstructured":"Miyakawa K, Jeremiah SS, Ogawa M, Nishi M, Ohnishi M, Ryo A. Crosstalk between the innate immune system and selective autophagy in hepatitis B virus infection. Autophagy. 2022;18:2006\u20137.","journal-title":"Autophagy"},{"key":"3138_CR33","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41467-022-28171-5","volume":"13","author":"K Miyakawa","year":"2022","unstructured":"Miyakawa K, Nishi M, Ogawa M, Matsunaga S, Sugiyama M, Nishitsuji H, Kimura H, Ohnishi M, Watashi K, Shimotohno K, et al. Galectin-9 restricts hepatitis B virus replication via p62\/SQSTM1-mediated selective autophagy of viral core proteins. Nat Commun. 2022;13:531.","journal-title":"Nat Commun"},{"key":"3138_CR34","first-page":"1425","volume":"11","author":"H You","year":"2023","unstructured":"You H, Wang F, Li T, Xu X, Sun Y, Nan Y, Wang G, Hou J, Duan Z, Wei L, et al. Guidelines for the Prevention and Treatment of Chronic Hepatitis B (version 2022). J Clin Transl Hepatol. 2023;11:1425\u201342.","journal-title":"J Clin Transl Hepatol"},{"key":"3138_CR35","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402\u20138.","journal-title":"Methods"},{"key":"3138_CR36","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.clinre.2016.12.006","volume":"41","author":"G Deng","year":"2017","unstructured":"Deng G, Ge J, Liu C, Pang J, Huang Z, Peng J, Sun J, Hou J, Zhang X. Impaired expression and function of TLR8 in chronic HBV infection and its association with treatment responses during peg-IFN-\u03b1-2a antiviral therapy. Clin Res Hepatol Gastroenterol. 2017;41:386\u201398.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"3138_CR37","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s12985-023-02119-7","volume":"20","author":"H Luo","year":"2023","unstructured":"Luo H, Tan G, Hu X, Li Y, Lei D, Zeng Y, Qin B. Triple motif proteins 19 and 38 correlated with treatment responses and HBsAg clearance in HBeAg-negative chronic hepatitis B patients during peg-IFN-\u03b1 therapy. Virol J. 2023;20:161.","journal-title":"Virol J"},{"key":"3138_CR38","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1128\/JVI.01292-06","volume":"81","author":"V Christen","year":"2007","unstructured":"Christen V, Duong F, Bernsmeier C, Sun D, Nassal M, Heim MH. Inhibition of alpha interferon signaling by hepatitis B virus. J Virol. 2007;81:159\u201365.","journal-title":"J Virol"},{"key":"3138_CR39","doi-asserted-by":"publisher","first-page":"1034968","DOI":"10.3389\/fimmu.2022.1034968","volume":"13","author":"Q Li","year":"2022","unstructured":"Li Q, Sun B, Zhuo Y, Jiang Z, Li R, Lin C, Jin Y, Gao Y, Wang D. Interferon and interferon-stimulated genes in HBV treatment. Front Immunol. 2022;13:1034968.","journal-title":"Front Immunol"},{"key":"3138_CR40","doi-asserted-by":"publisher","first-page":"13383","DOI":"10.1038\/s41598-017-13747-9","volume":"7","author":"J Huang","year":"2017","unstructured":"Huang J, Zhang K, Chen W, Liao J, Luo X, Chen R. Switching to PegIFN\u03b1-2b leads to HBsAg loss in patients with low HBsAg levels and HBV DNA suppressed by NAs. Sci Rep. 2017;7:13383.","journal-title":"Sci Rep"},{"key":"3138_CR41","doi-asserted-by":"publisher","first-page":"25","DOI":"10.14218\/JCTH.2017.00072","volume":"6","author":"P Hu","year":"2018","unstructured":"Hu P, Shang J, Zhang W, Gong G, Li Y, Chen X, Jiang J, Xie Q, Dou X, Sun Y, et al. HBsAg Loss with Peg-interferon Alfa-2a in Hepatitis B Patients with Partial Response to Nucleos(t)ide Analog: New Switch Study. J Clin Transl Hepatol. 2018;6:25\u201334.","journal-title":"J Clin Transl Hepatol"},{"key":"3138_CR42","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1002\/hep.26436","volume":"58","author":"MJ Sonneveld","year":"2013","unstructured":"Sonneveld MJ, Hansen BE, Piratvisuth T, Jia JD, Zeuzem S, Gane E, Liaw YF, Xie Q, Heathcote EJ, Chan HL, Janssen HL. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology. 2013;58:872\u201380.","journal-title":"Hepatology"},{"key":"3138_CR43","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41591-025-04049-z","volume":"32","author":"GL Wong","year":"2026","unstructured":"Wong GL, Yuen MF, Lin B, Douglas MW, Hu P, Xie Q, Lv F, Tak WY, Leerapun A, Kim DJ, et al. Elebsiran and PEG-IFN\u03b1 for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial. Nat Med. 2026;32:151\u20139.","journal-title":"Nat Med"},{"key":"3138_CR44","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1186\/s12879-023-08443-1","volume":"23","author":"Q Tang","year":"2023","unstructured":"Tang Q, Ye J, Zhang Y, Zhang P, Xia G, Zhu J, Wei S, Li X, Zhang Z. Establishment of a multi-parameter prediction model for the functional cure of HBeAg-negative chronic hepatitis B patients treated with pegylated interferon\u03b1 and decision process based on response-guided therapy strategy. BMC Infect Dis. 2023;23:456.","journal-title":"BMC Infect Dis"},{"key":"3138_CR45","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3892\/etm.2023.12286","volume":"26","author":"S Mimura","year":"2023","unstructured":"Mimura S, Fujita K, Takuma K, Nakahara M, Oura K, Tadokoro T, Tani J, Morishita A, Ono M, Himoto T, Masaki T. Predictors of therapeutic response to peginterferon \u03b1\u20132a and nucleos(t)ide analog combination therapy for HBeAg\u2013negative chronic hepatitis B: 1\u2013year follow\u2013up after treatment. Exp Ther Med. 2023;26:587.","journal-title":"Exp Ther Med"},{"key":"3138_CR46","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/hep.23722","volume":"52","author":"V Rijckborst","year":"2010","unstructured":"Rijckborst V, Hansen BE, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, Simon K, Akarca US, Flisiak R, Verhey E, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology. 2010;52:454\u201361.","journal-title":"Hepatology"},{"key":"3138_CR47","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1007\/s12072-024-10666-6","volume":"18","author":"PX Zhang","year":"2024","unstructured":"Zhang PX, Tang QQ, Zhu J, Deng WY, Zhang ZH. Predictive models for functional cure in patients with CHB receiving PEG-IFN therapy based on HBsAg quantification through meta-analysis. Hepatol Int. 2024;18:1110\u201321.","journal-title":"Hepatol Int"},{"key":"3138_CR48","doi-asserted-by":"publisher","first-page":"894410","DOI":"10.3389\/fimmu.2022.894410","volume":"13","author":"WX Wang","year":"2022","unstructured":"Wang WX, Jia R, Gao YY, Liu JY, Luan JQ, Qiao F, Liu LM, Zhang XN, Wang FS, Fu J. Quantitative anti-HBc combined with quantitative HBsAg can predict HBsAg clearance in sequential combination therapy with PEG-IFN-\u03b1 in NA-suppressed chronic hepatitis B patients. Front Immunol. 2022;13:894410.","journal-title":"Front Immunol"},{"key":"3138_CR49","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1093\/infdis\/jiy270","volume":"218","author":"F van B\u00f6mmel","year":"2018","unstructured":"van B\u00f6mmel F, van B\u00f6mmel A, Krauel A, Wat C, Pavlovic V, Yang L, Deichsel D, Berg T, B\u00f6hm S. Serum HBV RNA as a Predictor of Peginterferon Alfa-2a Response in Patients With HBeAg-Positive Chronic Hepatitis B. J Infect Dis. 2018;218:1066\u201374.","journal-title":"J Infect Dis"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-026-03138-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-026-03138-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-026-03138-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T01:01:44Z","timestamp":1777510904000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12985-026-03138-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,22]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3138"],"URL":"https:\/\/doi.org\/10.1186\/s12985-026-03138-w","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,22]]},"assertion":[{"value":"11 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was received from Ethical Review Committee of the First Affiliated Hospital of Chongqing Medical University, Chongqing, China (Reference number: 2023\u2009\u2212\u2009311), and the registration process was successfully completed on the designated website (\n                      \n                      ). All patients submitted written informed consent for their participation in the study. The study was conducted in adherence to relevant laws and institutional protocols and in accordance with the ethical standards of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have approved the final version of the manuscript. Consent for the publication of data, images, or information was obtained from all participants (or their legal guardians) where applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"118"}}